Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

69 results about "Colorectal Tumors" patented technology

Colorectal cancer is a malignant tumour that starts in cells of the colon or rectum. Malignant means it is a cancerous tumour that can spread, or metastasize, to other parts of the body.

Humanized antibodies directed against A33 antigen

A33 antigen binding proteins are described for use in the diagnosis or treatment of colorectal tumors and metastases arising therefrom. The binding protein may be a humanized A33 antibody, including complete antibody molecules, fragments thereof, and particularly, multivalent monospecific proteins comprising two, three, four or more antibodies or fragments thereof, bound to each other by a cross-linking agent. For diagnosis or therapy, the humanized A33 antibody may be linked to a reporter or effector molecule.
Owner:CELLTECH LTD

Tumor marker related to colorectal cancer and application

The invention discloses a tumor marker related to colorectal cancer and application. The tumor marker is lncRNA (long noncoding RNA) and is located on the seventeenth chromosome of chr17: 47785696-47797422, a nucleotide sequence of the lncRNA is shown in SEQ ID NO.1 is named as lncRNA-KAT7. According to the lncRNA-KAT7 sequence, specific real-time fluorescent quantitative PCR primer can be designed and synthesized to be used for preparing preparation for colorectal cancer diagnosis or treating effect prediction. By means of the real-time fluorescent quantitative PCR preparation, expression level of lncRNA-KAT7 is detected in colorectal cancer clinical case specimen, expression of the lncRNA-KAT7 in the colorectal cancer is found to be obviously reduced, the lncRNA-KAT7 has obvious statistic significance (p<0.05), and low expression of the lncRNA-KAT7 in the colorectal cancer is closely related to colorectal tumor differentiation, T staging, invasion and metastasis. The result shows that the lncRNA-KAT7 can serve as the tumor marker of the colorectal cancer and can be used for preparing preparation or kits applied to auxiliary diagnosis, treating effect prediction and prognosis of the colorectal cancer.
Owner:CHENZHOU NO 1 PEOPLES HOSPITAL

Method for detection of colorectal tumor

InactiveUS20120034605A1High sensitivitySimply detectMicrobiological testing/measurementTwist HomologTWIST1 gene
Disclosed is a method for determining the presence or absence of a colorectal tumor, specifically colorectal cancer or colorectal adenoma, with high sensitivity and high specificity by employing the methylation of DNA as a measure. Also disclosed is a kit for carrying out the method. Specifically, measurement is made on the degree of methylation of one or more CpG sequences contained in the region lying between positions -477 to -747, more preferably a CGCG sequence contained in the region lying between positions -688 to -691, in TWIST1 gene (Homo sapiens twist homolog 1; Drosophila gene) located on the genome sequence of a test cell.
Owner:A T LT

Primer and probe for detecting methylation levels of BMP3 and NDRG4 in biological sample

The invention provides a primer and a probe for detecting methylation levels of BMP3 and NDRG4 in a biological sample and further provides a method and a kit for detecting the methylation levels of BMP3 and NDRG4 in the biological sample by virtue of the primer and the probe. The primer and the probe have high sensitivity and specificity; by virtue of the detection method, early diagnosis information of colorectal tumors can be provided, and a simple, convenient and feasible solution is provided for the early detection of the colorectal tumors.
Owner:HANGZHOU NEW HORIZON HEALTH TECH CO LTD

Methods for the detection of colorectal tumors

Disclosed is a method for determining the presence or absence of a colorectal tumor, specifically colorectal cancer or colorectal adenoma, with high sensitivity and high specificity by employing the methylation of DNA as a measure. Also disclosed is a kit for carrying out the method. Specifically, measurement is made on the degree of methylation of one or more CpG sequences contained in the region lying between positions -477 to -747, more preferably a CGCG sequence contained in the region lying between positions -688 to -691, in TWIST1 gene (Homo sapiens twist homolog 1; Drosophila gene) located on the genome sequence of a test cell.
Owner:A T LT

A traditional Chinese medicine composition preventing and treating colorectal precancerous lesion, a preparing method thereof and applications of the composition

A traditional Chinese medicine composition preventing and treating colorectal precancerous lesion, a preparing method thereof and applications of the composition are disclosed. The composition includes 20-60 parts of hedyotis, 9-27 parts of lightyellow sophora root, 15-45 parts of radix codonopsis, 12-36 parts of largehead atractylodes rhizome, 12-36 parts of smoked plum, 3-9 parts of rhizoma coptidis, 6-18 parts of rhizoma zingiberis praeparatum and 30-90 parts of coix seed. Prescription screening is performed according to a traditional Chinese medicine theory that is treatment based on syndrome differentiation and according to pathogenesis of intestinal cancer. Treatment mechanisms of invigorating the spleen, benefiting qi, removing heat, drying dampness, detoxifying, removing stasis, and strengthening and consolidating body resistance are adopted innovatively. Experiment results show that the composition can obviously improve AOM-DSS induced symptoms such as body mass decrease, loose stool, and hemafecia, that the composition can reduce the occurrence rate of a colorectal lesion that is mouse colon tumor, and that the composition has significant activity resisting solid colorectal tumor and intestine cytoma. Disassembled prescription experiment results show that medicine materials of the composition are irreplaceable and the composition is a scientific prescription.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

Integrated Analyses of Breast and Colorectal Cancers

Genome-wide analysis of copy number changes in breast and colorectal tumors used approaches that can reliably detect homozygous deletions and amplifications. The number of genes altered by major copy number changes—deletion of all copies or amplification of at least twelve copies per cell—averaged thirteen per tumor. These data were integrated with previous mutation analyses of the Reference Sequence genes in these same tumor types to identify genes and cellular pathways affected by both copy number changes and point alterations. Pathways enriched for genetic alterations include those controlling cell adhesion, intracellular signaling, DNA topological change, and cell cycle control. These analyses provide an integrated view of copy number and sequencing alterations on a genome-wide scale and identify genes and pathways that are useful for cancer diagnosis and therapy.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof

In vitro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such in vitro kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed.
Owner:THOMAS JEFFERSON UNIV

Antibodies and Fv fragment recognizing antigen IOR C2

Novel recombinant antibodies from murine antibody IOR C5 produced by the hybridoma deposited with the ECCC 97061101. The recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody, and single chain Fv fragment. The chimeric antibody contains the variable domains of the murine immunoglobuline and the constant regions of the human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine frameworks regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences.
Owner:CENT DE INMUNOLOGIA MOLECULAR CENT DE INMUNOLO

Method for building improved orthotopic transplantation tumor model of colorectal tumor in nude mice

The invention discloses a transplantation tumor model of colorectal tumor for medical scientific research, which is produced by improving the orthotopic transplantation tumor model of colorectal tumor in nude mice. The invention aims to overcome the defect that the orthotopic transplantation tumor model of colorectal tumor has high intestinal obstruction incidence rate and short model animal survival time and is not suitable for long-time experiments. In the invention, the prepared tumor is transplanted close to the blood vessel in mesocolon. The method comprises the following steps: (1) preparation of tumor: injecting single cell suspension of the tumor cell to subcutis of nude mice and preparing the source of the transplantation tumor; (2) transplanting the prepared tumor close to the blood vessel in mesenterium of nude mice but not the serosa of the intestinal tube; and (3) raising the nude mice in an aseptic laminar flow room, controlling the room temperature to be (25+ / -1) DEG C and relative humidity to be 40-50% and continuously observing the nude mice. The animal model built by the invention can reproduce the natural clinical pathology process of human colorectal tumor, can not suffer from obstruction of the lumen in the digestive tract in the short term and has transfer mode similar to that of the patients.
Owner:LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE

Method for constructing colorectal tumor state evaluation model and application

The invention relates to the field of gene detection and bioinformatics. The invention discloses an application of a complex disease state evaluation method constructed based on high-throughput sequencing data and clinical phenotypes in a colorectal tumor state evaluation model. The invention discloses a method for mining colorectal cancer markers based on transcriptome data, exon group / genome data and clinical phenotypes. The invention designs a set of calculation method for constructing a colorectal cancer state evaluation model by integrating high-throughput sequencing data and clinical phenotypes, biomarkers related to colorectal cancer are screened out, and a corresponding disease state evaluation model is formed. The markers considering both accuracy and mechanism interpretability are constructed through the method and can be used for colorectal cancer prognosis evaluation, treatment effect prediction, treatment scheme assistant decision making and the like.
Owner:上海市生物医药技术研究院

Primers, probes and kit for detecting specific methylation of colorectal tumor

The invention discloses primers, probes and a kit for detecting the specific methylation of a colorectal tumor, and belongs to the technical field of biological detection. The primers and the probes include the forward primer, the backward primer and the probe of an SDC2 gene, the forward primer, the backward primer and the probe of an SFRP2 gene, and the forward primer, the backward primer and the probe of an ACTB reference gene. The kit comprises the primers and the probe. The primers, probes and kit for detecting the specific methylation of the colorectal tumor are designed to Chinese and have the advantages of high specificity and sensitivity, sampling is free of invasion and convenient since excrements are used as the sample, the ACTB is selected as the reference gene and is detectedin the same tube together with the SFRP2 gene and the SDC2 gene, the detection result is more accurate, and the primers, probes and kit have great significance in early finding precancerous lesions and early colorectal cancers.
Owner:阿吉安(福州)基因医学检验实验室有限公司

Application of FGF21 in preparation of medicine for treating colorectal cancer

The invention discloses an application of FGF21 in preparation of a medicine for treating colorectal cancer, and belongs to the technical field of medicines. The FGF21 protein provided by the invention is a secretory protein composed of about 210 amino acids. The invention finds for the first time that the FGF21 has the effect of treating colorectal tumor, and cytological experiments and animal experiments prove that the FGF21 can inhibit proliferation, invasion and migration of a colorectal tumor cell line, and can obviously reduce the size of a tumor focus in a mouse model. The medicine which is used for treating colorectal cancer and is prepared by taking the FGF21 as an active substance has the effects of being good in safety, long in medicine effect lasting time, capable of protectingorgans from being damaged and capable of improving lipid metabolism disorder.
Owner:无锡代达康健生物医药科技有限公司

Primers, probes and kit used for human colorectal tumor specific methylation detection and application of primers and probes used for human colorectal tumor specific methylation detection

The invention relates to primers and probes used for human colorectal tumor specific methylation detection and application thereof and a kit used for human colorectal tumor specific methylation detection. According to the technical scheme, for a promoter high GC area of a human genome SFRP2 gene, a pair of the methylation specific Real-time PCR primers and the corresponding probes are designed. The primers and the probes are adopted for conducting Real-time PCR detection on a to-be-detected sample subjected to sulfite transformation, according to an amplification result, whether or not the to-be-detected sample is an SFRP2 gene methylation sample is judged, and then whether or not the to-be-detected sample is a colorectal tumor sample is judged. The primers and the probes used for human colorectal tumor specific methylation detection and the application thereof and the kit used for human colorectal tumor specific methylation detection have the beneficial effects that the specificity ishigh, wherein a colorectal tumor specific marker is adopted, and the specificity of colorectal tumor detection is up to 92.3%; the sensitivity is high, wherein the total sensitivity of colorectal tumor detection is 76.3%, specifically, the sensitivity of colorectal cancer detection is 84.6%, and the sensitivity of precancerous lesion detection is 58.3%.
Owner:HANGZHOU HEYI GENE TECH

Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof

In vi tro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such in vitro kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed.
Owner:THOMAS JEFFERSON UNIV

Application of miRNA-5571 in preparation of drugs for resisting colorectal tumor

The invention belongs to the field of biological medicines, and relates to an application of miRNA-5571 or a mimic thereof or an accelerant thereof in the preparation of drugs for resisting colorectaltumor. The research finds that by transfecting miR-5571 or the mimics thereof, the migration and invasion capacity of colorectal tumor cells can be effectively inhibited. The invention finds the inhibition effect of the miR-5571 on the colorectal tumor for the first time, and the miR-5571 has important significance in reducing the death rate of the colorectal tumor.
Owner:SUN YAT SEN UNIV +1

Application of miR-24-1-5p to colorectal tumor

The invention relates to application of miR-24-1-5p to colorectal tumor. An expression condition of the miR-24-1-5p in a colorectal tumor tissue and five types of colorectal tumor cell lines is detected by fluorescent quantitative PCR (Polymerase Chain Reaction) and a result finds out that the expression of the miR-24-1-5p in the colorectal tumor tissue and cells is obviously regulated downwards and the miR-24-1-5p plays an important regulation and control role in occurring and development processes of the colorectal tumor. By constructing an miR-24-1-5p overexpression carrier, a colorectal tumor cell Caco2 and HCT-116 cells are transfected, and MTT (Methyl Thiazolyl Tetrazolium), cell scratch, Transwell and plate cloning experiments are used for researching influences of the miR-24-1-5p on proliferation and migration of the colorectal tumor cells; results show that the miR-24-1-5p can be used for remarkably inhibiting the proliferation and the migration of the colorectal tumor cells and can be used for a biological preparation for treating the colorectal tumor.
Owner:LIAONING UNIVERSITY

Differential expression of genes in microsatellite instability

The present invention relates to nucleic acid sequences which are overexpressed in colorectal tumors which display a high level of microsatellite instability (MSI-H) vs. tumors displaying a low level of microsatellite instability (MSS), and can thus be used to identify MSI-H in a patient, and be used further to facilitate patient prognosis, monitor disease progression / regression, identify appropriate treatment regimes, and evaluate the efficacy of treatment.
Owner:BAYER HEALTHCARE LLC +1

Specimen for detecting infiltrative large intestine tumors

An object of the present invention is to provide a method for non-invasively diagnosing invasiveness or degree of invasion of colorectal tumors.The present invention is characterized in that it enables to obtain a specimen that can be used to detect invasive colorectal tumors by spraying a washing fluid onto the colonic mucous layer of a subject to detach the mucus from the mucous layer, and collecting the detached mucus together with the washing fluid.
Owner:SAPPORO MEDICAL UNIVERSITY

Method for detecting and identifying subspecies of fusobacterium nucleatum

PendingCN112980975AHelps to explore relationshipsHelp to explore epidemiological characteristicsMicrobiological testing/measurementMicroorganism based processesDiseaseColorectal tumor
The invention relates to the technical field of biological medicines, in particular to a method for detecting and identifying subspecies of fusobacterium nucleatum. The fusobacterium nucleatum is closely associated with various diseases, and recent research shows that the fusobacterium nucleatum can promote generation and development of colorectal tumors. However, an accurate and visual detection method for distinguishing different subspecies of the fusobacterium nucleatum is lacked at present. Different subspecies of the fusobacterium nucleatum are different in biological characteristic, colonization and pathogenicity, so that accurate subspecies identification has far-reaching significance for knowing the pathogenic mechanism of the fusobacterium nucleatum. According to the invention, a group of specific DNA sequences for identifying the fusobacterium nucleatum subspecies are provided, corresponding detection primers are designed, and the application of the detection primers in subspecies level detection and identification of the fusobacterium nucleatum is explained. According to the invention, the composition and the source of the subspecies of the fusobacterium nucleatum in the focus can be disclosed, and the relationship between different subspecies and diseases and related epidemiological characteristics can be explored.
Owner:SHANGHAI TENTH PEOPLES HOSPITAL

A tumor marker related to colorectal cancer and its application

The invention discloses a tumor marker related to colorectal cancer and application. The tumor marker is lncRNA (long noncoding RNA) and is located on the seventeenth chromosome of chr17: 47785696-47797422, a nucleotide sequence of the lncRNA is shown in SEQ ID NO.1 is named as lncRNA-KAT7. According to the lncRNA-KAT7 sequence, specific real-time fluorescent quantitative PCR primer can be designed and synthesized to be used for preparing preparation for colorectal cancer diagnosis or treating effect prediction. By means of the real-time fluorescent quantitative PCR preparation, expression level of lncRNA-KAT7 is detected in colorectal cancer clinical case specimen, expression of the lncRNA-KAT7 in the colorectal cancer is found to be obviously reduced, the lncRNA-KAT7 has obvious statistic significance (p<0.05), and low expression of the lncRNA-KAT7 in the colorectal cancer is closely related to colorectal tumor differentiation, T staging, invasion and metastasis. The result shows that the lncRNA-KAT7 can serve as the tumor marker of the colorectal cancer and can be used for preparing preparation or kits applied to auxiliary diagnosis, treating effect prediction and prognosis of the colorectal cancer.
Owner:CHENZHOU NO 1 PEOPLES HOSPITAL

Convenient food for conditioning colorectal neoplasms

The invention provides convenient food for conditioning colorectal neoplasms. L-glutamine acts as the main material of the convenient food, and according to the constitutive characters of patients suffering from colorectal neoplasms, the convenient food is prepared by the steps of reasonably and specifically blending food and drug herbal extracts, such as dendrobe, semen coicis, jerusalem artichoke, Chinese yam, dandelion, hawthorn, ficus carica L, honeysuckle, endothelium corneum gigeriae galli, hericium erinaceus, sea-buckthorn, fingered citron, medlar, semen raphani, pawpaw, apricot kernels, raspberry, portulaca oleracea and fructus amomi by utilizing the essence of the theory of traditional Chinese medicine, extracting the herbal extracts by a biological enzymolysis or prehydrolysis SBE technique, and then adding prebiotics, ammonia acids, oligopeptide, vitamins and minerals and mixing so as to prepare the convenient food. The convenient food prepared according to the formula provided by the invention is easy to dissolve, can be absorbed and utilized rapidly, can improve the nutritional condition of the patients suffering from colorectal neoplasms, can be used for assisting in improving the organism immunity by the effect of the bioactive components in the food and drug herbal extracts, plays roles of inhibiting and resisting cancers, and is suitable for patients suffering from colorectal neoplasms or patients which suffering from cancers and receiving radiotherapy or chemotherapy to eat, and therefore, the convenient food has the unique advantage of integrating the three efficacies of dietary therapy, prevention and conditioning.
Owner:胡安然

Application of miRNA-1293 in preparation of anti-colorectal tumor drug

The invention belongs to the field of biomedicine and particularly relates to application of miRNA-1293 or miRNA-1293 mimics or miRNA-1293 accelerants in preparation of an anti-colorectal tumor drug.The invention finds for the first time that the miRNA-1293 can inhibit proliferation of colorectal tumor cells and promote apoptosis of the colorectal tumor cells, which has important significance inreducing the death rate of colorectal tumor.
Owner:THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV +1

Method and system for determining colorectal tumor cells on basis of KRAS and NDRG4 genes

The invention provides a method and system for determining colorectal tumor cells on the basis of KRAS and NDRG4 genes. The method includes: acquiring the KRAS gene and NDRG4 gene of a to-be-determined sample, and performing methylation on the NDRG4 gene; sequencing the KRAS gene and the NDRG4 gene after the methylation to obtain a KRAS gene sequencing result and a NDRG4 gene sequencing result; performing first comparison on the gene sequence of a first target position in the KRAS gene sequencing result and first reference sequence to calculate KRAS gene mutation rate; performing second comparison on the gene sequence of a second target position in the NDRG4 gene sequencing result and second reference sequence to calculate NDRG4 gene methylation linkage rate; determining whether the to-be-determined sample has colorectal tumor cells or not according to the KRAS gene mutation rate and the NDRG4 gene methylation linkage rate. By the method and system high in sensitivity, whether the sample has the colorectal tumor cells or not can be determined fast, simply and specifically.
Owner:SHANGHAI REALBIO TECH CO LTD

Early CRC (Colorectal Cancer) diagnostic marker circ4953 and application thereof

The invention provides an early CRC (Colorectal Cancer) diagnostic marker. The diagnostic marker is circular RNA circ4953, and has the nucleotide sequence shown as SEQ ID No.1. During the applicationof the circular RNA circ4953 to preparation of an early CRC diagnosis tool, the tool is a kit, and comprises a primer pair for amplifying and specifically recognizing the nucleotide sequence of the circular RNA circ4953. The occurrence of the early colorectal tumor diseases can be explicitly and clearly expressed; the expression of the marker in a plurality of early CRC tissue samples is obviouslyhigher than the expression in a control tissue sample (normal tissues with a distance being 5cm from tumor tissues); and the expression of the marker in a plurality of early CRC patient blood serum samples is obviously higher than the expression in control healthy blood serum samples.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

Methods and systems for evaluation of immune cell infiltrate in stage iv colorectal cancer

Immune context scores are calculated for stage IV colorectal tumor tissue samples using non-continuous scoring functions. Feature metrics for at least one immune cell marker are calculated for a region or regions of interest, the feature metrics including at least a density of human CD8+ cells in a region of interest including a tumor core to generate an immune context score. The immune context score can then be used as a predictive metric (e.g. likelihood of response to a particular treatment course). The immune context score may then be incorporated into diagnostic and / or treatment decisions.
Owner:VENTANA MEDICAL SYST INC +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products